NPM1突变急性髓系白血病的原始细胞表型与共突变影响疾病生物学及结局
该多中心队列纳入239例NPM1突变急性髓系白血病(AML-NPM1),按原始细胞表型分为单核、髓系和双阴性三组。双阴性组TET2和IDH1/2突变显著更常见且无复发生存和总生存显著更长,提示表型与遗传异质性影响预后。
要点
- NPM1突变AML可按原始细胞表型分为单核、髓系和双阴性三组。
- 双阴性组TET2/IDH1/2突变常见且生存优于其他两组。
- 表型分组有助于识别NPM1突变AML的预后差异。
核心结论
- NPM1突变AML中免疫表型定义的亚组存在生物学差异,并可能具有预后意义。
研究设计与样本
- 多中心队列纳入239例NPM1突变急性髓系白血病(AML-NPM1)病例。
主要发现
- 共突变最常见于DNA甲基化基因(81%)、FLT3(48%)和RAS通路基因(30%)。
- 双阴性组TET2和IDH1/2突变占96%,高于髓系组39%和单核组48%(P < .0001)。
- 双阴性组DNMT3A突变占27%,低于髓系组44%和单核组54%(P = .002)。
- 双阴性组无复发生存64.7个月、总生存66.5个月,优于单核组(20.6、44.3个月)和髓系组(8.4、20.2个月)。
关键数值与推荐
- 双阴性AML-NPM1定义为原始细胞CD34和HLA-DR均阴性(n = 74)。
- 单核AML-NPM1定义为原始细胞显示单核分化(n = 93)。
- 髓系AML-NPM1定义为原始细胞缺乏单核分化(n = 72)。
临床怎么用
- 对NPM1突变AML可结合原始细胞表型(单核、髓系、双阴性)与共突变模式评估预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent work has identified distinct molecular subgroups of acute myeloid leukemia (AML) with implications for disease classification and prognosis. AML with mutated NPM1 (AML-NPM1) represents a distinct entity in the revised 2017 World Health Organization classification, but relatively little work has examined the clinical significance of phenotypic and genetic heterogeneity within this group. A multi-institutional cohort of 239 AML-NPM1 cases included 3 phenotypic groups: cases with blasts showing monocytic differentiation (n = 93; monocytic AML-NPM1), cases lacking monocytic differentiation (n = 72; myeloid AML-NPM1), and cases where blasts were negative for both CD34 and HLA-DR (n = 74; double-negative [DN] AML-NPM1). Genotypic diversity typical of AML-NPM1 was seen, with comutations occurring most commonly in DNA methylation genes (81% of cases), FLT3 (48%; including internal tandem duplication and tyrosine kinase domain mutations), and RAS pathway genes (30%). However, the comutation pattern differed by blast phenotype. TET2 and IDH1/2 mutations were significantly more common in DN AML-NPM1 (96% of cases) than in myeloid (39%) or monocytic AML-NPM1 (48%; P < .0001). Conversely, DNMT3A mutations were significantly less common in DN AML-NPM1 (27%) than in myeloid (44%) or monocytic cases (54%; P = .002). Furthermore, the 3 phenotypic groups showed significant differences in outcome, with DN AML-NPM1 showing significantly longer relapse-free (RFS) and overall survival (OS) (64.7 and 66.5 months, respectively) than monocytic AML-NPM1 (RFS, 20.6 months; OS, 44.3 months) or myeloid AML-NPM1 (RFS, 8.4 months; OS, 20.2 months; P < .0001 and P = .01 for RFS and OS, respectively). Our findings highlight biologic differences within immunophenotypically defined subgroups of NPM1-mutated AML that may impart prognostic significance.
引用
- Mason EF, Hasserjian RP, Aggarwal N, et al. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv. 2019. PMID: 31698462. doi:10.1182/bloodadvances.2019000328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。